I
iBio, Inc.
IBIOCIK 0001420720NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30
Period
FY 2025
Revenue
$400.0K
Net Income
$-18.38M
Total Assets
$23.18M
Equity
$14.88M
Shares Out
49.68M
Op. Cash Flow
$-15.30M
Business
iBio, Inc. is a preclinical-stage biotechnology company developing precision antibodies for obesity and cardiometabolic disease using an AI-powered drug discovery platform. The company's lead programs include IBIO-610 (Activin E antibody), IBIO-600 (anti-myostatin antibody), and a myostatin × Activin A bispecific antibody, all designed to address unmet needs in weight loss and metabolic health. iBio also maintains a pre-clinical immuno-oncology pipeline available for partnering, including programs targeting CD25, TROP-2, MUC16, EGFRvIII, and CCR8. The company conducts R&D in San Diego and anticipates initiating first human clinical trials in late fiscal 2026 or early fiscal 2027.
Summary from 10-K filed 2025-09-05
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue | 400,000 | 225,000 | 0 | — | — | |
| Research and development | 8 | 5 | 10 | 10 | 10 | |
| General and administrative | 11 | 12 | 19 | 22 | 22 | |
| Total operating expenses | 19 | 17 | 29 | 32 | 32 | |
| Operating loss | −19 | −17 | −29 | −30 | −31 | |
| Interest expense | −212,000 | −172,000 | −83,000 | — | — | |
| Interest income | 437,000 | 363,000 | 213,000 | 177,000 | 140,000 | |
| Gain on sale of intellectual property | — | 1 | — | — | — | |
| Total other income | 225,000 | 1 | 32,000 | 184,000 | 8 | |
| Net loss from continuing operations | −18 | −15 | −29 | −30 | — | |
| Loss from discontinued operations | — | −9 | −36 | −21 | — | |
| Net loss | −18 | −25 | −65 | −50 | −23 | |
| Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations | −1.75 | −4.03 | −47.88 | −3.39 | — | |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations | −1.75 | −4.03 | −47.88 | −3.39 | — | |
| Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations | — | −2.47 | −58.31 | −2.39 | — | |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations | — | −2.47 | −58.31 | −2.39 | — | |
| Loss per common share attributable to iBio, Inc. stockholders - basic - total | −1.75 | −6.5 | −106.19 | −5.78 | −3 | |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - total | −1.75 | −6.5 | −106.19 | −5.78 | −3 | |
| Weighted-average common shares outstanding - basic | 10 | 4 | 612,000 | 9 | 8 | |
| Weighted-average common shares outstanding - diluted | 10 | 4 | 612,000 | 9 | 8 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9 | 14 | 4 | 23 | — | |
| Subscription receivable | 105,000 | — | 204,000 | — | — | |
| Promissory note receivable and accrued interest | — | 713,000 | — | — | — | |
| Prepaid expenses and other current assets | 1 | 749,000 | 664,000 | 2 | — | |
| Total Current Assets | 10 | 16 | 26 | 45 | — | |
| Restricted cash | 210,000 | 215,000 | 253,000 | 6 | — | |
| Promissory note receivable | 1 | 1 | 2 | — | — | |
| Finance lease right-of-use assets, net of accumulated amortization | 68,000 | 339,000 | 610,000 | 74,000 | — | |
| Operating lease right-of-use asset | 2 | 2 | 3 | 3 | 2 | |
| Fixed assets, net of accumulated depreciation | 3 | 4 | 4 | 1 | — | |
| Intangible assets, net of accumulated amortization | 7 | 5 | 5 | 5 | — | |
| Security deposits | 26,000 | 26,000 | 50,000 | 29,000 | — | |
| Total Assets | 23 | 29 | 41 | 99 | — | |
| Accounts payable | 2 | 358,000 | 2 | 4 | — | |
| Accrued expenses | 1 | 2 | 5 | 4 | — | |
| Finance lease obligations - current portion | 53,000 | 299,000 | 272,000 | 46,000 | — | |
| Operating lease obligation - current portion | 490,000 | 436,000 | 389,000 | 91,000 | — | |
| Equipment financing payable - current portion | 64,000 | 178,000 | 160,000 | — | — | |
| Term promissory note - current portion | 766,000 | 218,000 | 13 | 22 | — | |
| Insurance premium financing payable | — | 123,000 | — | — | — | |
| Contract liabilities | 1 | 200,000 | 0 | 100,000 | — | |
| Total Current Liabilities | 6 | 4 | 22 | 30 | — | |
| Finance lease obligations - net of current portion | — | 53,000 | 351,000 | 30,000 | — | |
| Operating lease obligation - net of current portion | 2 | 3 | 3 | 4 | — | |
| Equipment financing payable - net of current portion | — | 63,000 | 241,000 | — | — | |
| Term promissory note - net of current portion | — | 766,000 | — | — | — | |
| Total Liabilities | 8 | 7 | 26 | 36 | — | |
| Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2025 and June 30, 2024; 19,349,201 and 8,623,676 shares issued and outstanding as of June 30, 2025 and June 30, 20243, respectively | 19,000 | 9,000 | 1,000 | 9,000 | — | |
| Additional paid-in capital | 347 | 335 | 304 | 288 | — | |
| Accumulated deficit | −332 | −314 | −289 | −224 | — | |
| Total Stockholders' Equity | 15 | 21 | 15 | 63 | — | |
| Total Liabilities and Stockholders' Equity | 23 | 29 | 41 | 99 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Consolidated net loss | −18 | −25 | — | — | — | |
| Share-based compensation | 2 | 2 | 4 | 4 | 2 | |
| Amortization of intangible assets | 20,000 | 20,000 | 126,000 | 401,000 | 291,000 | |
| Amortization of finance lease right-of-use assets | 271,000 | 271,000 | 224,000 | 599,000 | 2 | |
| Amortization of operating lease right-of-use assets | 351,000 | 321,000 | 356,000 | 516,000 | — | |
| Depreciation of fixed assets | 484,000 | 638,000 | 674,000 | 2 | 472,000 | |
| Gain on sale of fixed assets | — | 5 | −773,000 | — | — | |
| Gain on extinguishment of debt | — | −808,000 | — | — | — | |
| Accrued interest receivable on promissory note receivable | −62,000 | −88,000 | −75,000 | — | — | |
| Amortization of deferred financing costs | — | 120,000 | 242,000 | — | — | |
| Impairment of fixed assets | — | 3 | — | — | — | |
| Prepaid expenses and other current assets | −408,000 | 214,000 | 885,000 | 307,000 | −2 | |
| Security deposit | — | 24,000 | — | — | — | |
| Accounts payable | 2 | −1 | −625,000 | 1 | 48,000 | |
| Accrued expenses | −758,000 | −2 | 145,000 | 1 | 2 | |
| Operating lease obligations | −436,000 | −389,000 | −101,000 | −15,000 | — | |
| Contract liabilities | 250,000 | 200,000 | −100,000 | 7,000 | −1 | |
| Net cash used in operating activities | −15 | −19 | −30 | −37 | −30 | |
| Payment received for interest and principal on promissory note receivable | 758,000 | — | — | — | — | |
| Sale proceeds for intangible assets | — | 1 | — | — | — | |
| Purchase of fixed assets | −16,000 | −210,000 | −6 | −7 | −5 | |
| Sales proceeds for fixed assets | — | 116,000 | 3 | — | — | |
| Net cash provided by investing activities | 742,000 | 906,000 | 7 | −5 | −26 | |
| Proceeds from sales of common stock | 4 | 26 | 11 | — | — | |
| Proceeds from Warrant Inducement | 6 | — | — | — | — | |
| Payments made for costs to acquire capital | −294,000 | −88,000 | — | — | — | |
| Payments for fractional shares after reverse stock split | — | −7,000 | — | — | — | |
| Proceeds from the exercise of stock options | 131,000 | — | 0 | 77,000 | 54,000 | |
| Subscription receivable | — | 204,000 | — | — | — | |
| Payment of equipment financing loan | −178,000 | −160,000 | −99,000 | — | — | |
| Proceeds from term promissory note | — | 895,000 | — | — | — | |
| Payment of term promissory note | −218,000 | −88,000 | −9 | — | — | |
| Payment of term note payable | — | −2 | −9 | — | — | |
| Payment of finance lease obligation | −299,000 | −272,000 | −208,000 | −6 | −331,000 | |
| Net cash provided by financing activities | 9 | 24 | 2 | −6 | 79 | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | −6 | 7 | −21 | −49 | 22 | |
| Indefinite-lived intangible asset addition | 2 | — | — | — | — | |
| Shares issued to AstralBio for license fee | −750,000 | — | — | — | — | |
| Credit provided by AstralBio | −750,000 | — | — | — | — | |
| Insurance premium financing | — | 669,000 | — | — | — | |
| Subscription receivable | 105,000 | — | — | — | — | |
| Costs to raise capital paid directly from gross proceeds | 81,000 | 1 | — | — | — | |
| Costs to raise capital included in accrued expenses | 75,000 | 308,000 | — | — | — | |
| Issuance of warrant for term note payable obligation | — | 4 | — | — | — | |
| Reserves related to term promissory note included in prepaid expenses | — | 109,000 | — | — | — | |
| Costs related to tern promissory note paid directly from gross proceeds | — | 68,000 | — | — | — | |
| Cash paid during the period for interest | 212,000 | 749,000 | 687,000 | 1 | 2 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is iBio, Inc.'s CIK number?
iBio, Inc.'s SEC CIK number is 0001420720 (1420720). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find iBio, Inc.'s SEC filings?
All of iBio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did iBio, Inc. last report earnings?
iBio, Inc. (IBIO) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-059408). This is iBio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is iBio, Inc.'s most recent earnings 8-K?
iBio, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001104659-26-059408. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View iBio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →